Article Sidebar
Published:
May 16, 2018Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
The incidence of Australia antigen/antibody in acute and chronic liver disease
Abstract
The Australia (Au/SH) antigen was sought in patients with-acute viral hepatitis, chronic hepatitis, cirrhosis and hepatoma of the liver. Thirty per cent of patients with infectious hepatitis and 50% of patients with serum hepatitis had positive tests for Australia antigen. Antibody to the Australia antigen was present in 11-4% of patients with infectious hepatitis, and in 16% of patients with serum hepatitis, thus increasing the over-all positive test to 41.4% and 66% respectively. Screening for antibody is regarded as being of useful diagnostic assistance in patients with hepatitis and also for screening for hepatitis in potential blood donors.
The incidence of positive tests for Australia antiigen in chronic hepatitis was 26%, in cirrhosis 6% and in hepatoma 25%.
